Last reviewed · How we verify
NCT05697107
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
trial testing Ripretinib Oral Tablet in Gastrointestinal Stromal Tumors in 308 participants. Status unknown.
30 August 2022
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 308 |
| Start date | 20 May 2021 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ripretinib Oral Tablet — full drug profile →
Conditions studied
- Gastrointestinal Stromal Tumors — all drugs for Gastrointestinal Stromal Tumors →
Sponsor
Peking University
Who can join
18 and older, any sex, with Gastrointestinal Stromal Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang X, Zhang P, Qiu H, Fang Y, et al · · 2023 · cited 4× · PMID 37356078 · DOI 10.1007/s12325-023-02576-0
Verify or expand the search:
- PubMed search for NCT05697107
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Stromal Tumors
Currently open trials in the same condition.
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
- NCT06326346 — GIST Oral Paclitaxel(Liporaxel) · Phase 2 · recruiting
- NCT06087263 — Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation · Phase 2 · active not recruiting
- NCT05366816 — ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · Phase 2 · recruiting
- NCT05905887 — Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor · Phase 2 · recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05697107 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05697107.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing